Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
 Technology - EconoTimes)
HAMILTON, Bermuda, April 12, 2017 -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative off-the-shelf cellular therapy for the treatment of solid tumor cancers announced today that the European Patent Office has granted European Patent No. 2496244. This patent covers claims related to methods of combining chemotherapy and immunotherapy for the treatment of cancer. This new patent supports our scaffold approach to building an intellectual property portfolio allowing the novel combination of multiple modes of therapy for the treatment of cancer.
The compositions covered by the patent generally relate to genetically modified natural killer (NK) cells that confer resistance to a chemotherapy agent. The claimed compositions can be used to protect immune cells from drug induced toxicities, thereby allowing for the combined administration of immuno- and chemotherapy. When dosed together, such combinations can result in anti-tumor responses by the chemotherapy, and reduces the immunosuppressive effects of the tumor while driving enhanced immune-mediated tumor cell killing, a treatment termed “drug resistant immunotherapy” or DRI.
“As novel combinations of chemotherapy and immunotherapies expand across the treatment landscape, the ability to protect immune cells from the toxic effects of chemotherapy in order to maintain a functional immune response is crucial to better long-term outcomes in patients undergoing cancer treatment,” said William Ho, Chief Executive Officer of Incysus.
This patent is owned by Incysus’ academic collaborators at Emory University, the Children’s Hospital of Atlanta (CHOA) and the University of Alabama at Birmingham (UAB), and is licensed exclusively to Incysus for all therapeutic purposes. Incysus and the UAB are moving quickly towards an investigational new drug application (IND) filing with the U.S. FDA to test the safety and efficacy of DRI γδ T cells in patients with glioblastoma.
About Incysus, Ltd.
Incysus is a Bermuda incorporated company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified γδ T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation, cancers. The Company's immuno-oncology programs with its collaborators include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.
Contact: Incysus, Ltd (646) 820-8474 [email protected] www.incysus.com
